BioNTech SE (BNTX) EBITDA Margin (2018 - 2026)
BioNTech SE (BNTX) posted EBITDA Margin of 35.57% for Q4 2025, down 1052.1% sequentially from 3.09% in Q3 2025, and down 3558.0% YoY from 1.03% in Q4 2024.
Powered by 
Analysis
BioNTech SE (BNTX) EBITDA Margin (2018 - 2026) Analysis & Trends
BioNTech SE has reported EBITDA Margin for 8 years, with the latest figure at 35.57% in Q4 2025.
- Quarterly EBITDA Margin fell 3558.0% year-over-year to 35.57% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 46.98% (down 4694.0% YoY) and the FY2025 annual result came in at 48.95%, down 118.0% from the prior year.
- EBITDA Margin slipped to 35.57% in Q4 2025 per BNTX's latest filing, from 3.09% in the prior quarter.
- Over five years, EBITDA Margin peaked at 148.68% in Q2 2022 and troughed at 750.74% in Q2 2024.
- A 5-year average of 57.14% and a median of 4.5% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2025: EBITDA Margin tumbled 48458 bps in 2023, then surged 55860 bps in 2025.
- Over 5 years, EBITDA Margin stood at 0.0% in 2021, then jumped by 90606241 bps to 76.97% in 2022, then plunged by 54 bps to 35.58% in 2023, then sank by 100 bps to 0.0% in 2024, then sank by 790105 bps to 35.57% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 35.57%, 3.09%, and 192.14% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | BioNTech SE | 25.06 Bn | 11.41 Bn | 10.00 Mn | -897.82% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -897.82% |
| Mar 31, 2026 | -573.67% |
| Dec 31, 2025 | -35.57% |
| Sep 30, 2025 | -3.09% |
| Jun 30, 2025 | -192.14% |
| Mar 31, 2025 | -292.18% |
| Dec 31, 2024 | 12.49% |
| Sep 30, 2024 | 0.84% |
| Jun 30, 2024 | -750.74% |
| Mar 31, 2024 | -270.36% |
| Dec 31, 2023 | 35.58% |
| Sep 30, 2023 | 8.16% |
| Jun 30, 2023 | -335.90% |
| Mar 31, 2023 | 51.25% |
| Dec 31, 2022 | 76.97% |
| Sep 30, 2022 | 68.98% |
| Jun 30, 2022 | 69.13% |
| Mar 31, 2022 | 74.56% |
| Dec 31, 2021 | 84.95% |
| Sep 30, 2021 | 77.60% |